Efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis patients with different body mass index: a post hoc analysis based on a phase III trial
ObjectiveVunakizumab is effective and safe for treating moderate-to-severe plaque psoriasis patients. This post hoc analysis was intended to assess the effects of vunakizumab in patients with different body mass index (BMI).MethodsIn the phase III trial of vunakizumab (NCT04839016), 461 moderate-to-...
שמור ב:
| Principais autores: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2026-01-01
|
| סדרה: | Frontiers in Pharmacology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1685072/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|